Patent · US Active

Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors

US9505751B2 · kind B2 · utility

0Cited by
0References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 19, 2013
Grant dateNov 29, 2016
Priority date—
Expiry dateJun 19, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are substituted triazolopyrazine phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.